Literature DB >> 8550197

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.

D H Jones1, B W McBride, C Thornton, D T O'Hagan, A Robinson, G H Farrar.   

Abstract

Fimbriae from Bordetella pertussis have been encapsulated in poly(lactide-co-glycolide) microparticles of a size appropriate for uptake by the immune inductive tissues of the gastrointestinal tract. Mice were immunized by oral gavage with a single dose of 10 micrograms of microencapsulated fimbriae. The resulting immune responses were compared with those resulting from intraperitoneal injection of mice with equivalent amounts of fimbriae absorbed onto alhydrogel. The examination of serum and mucosal secretions, collected over a 6-week period, for specific antifimbrial antibodies clearly demonstrated that only orally immunized animals mounted measurable immune responses in external secretions. Six weeks after immunization, all immunized animals were protected against intranasal challenge with live B. pertussis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550197      PMCID: PMC173791          DOI: 10.1128/iai.64.2.489-494.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix, and Peyer's patches. An electron microscopic study.

Authors:  D E Bockman; M D Cooper
Journal:  Am J Anat       Date:  1973-04

Review 2.  Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.

Authors:  J Holmgren; N Lycke; C Czerkinsky
Journal:  Vaccine       Date:  1993-09       Impact factor: 3.641

3.  Development of a single-shot subunit vaccine for HIV-1.

Authors:  J L Cleland; M F Powell; A Lim; L Barrón; P W Berman; D J Eastman; J H Nunberg; T Wrin; J C Vennari
Journal:  AIDS Res Hum Retroviruses       Date:  1994       Impact factor: 2.205

Review 4.  Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies.

Authors:  W S Shalaby
Journal:  Clin Immunol Immunopathol       Date:  1995-02

Review 5.  New strategies for using mucosal vaccination to achieve more effective immunization.

Authors:  R I Walker
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

6.  Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  R Shahin; M Leef; J Eldridge; M Hudson; R Gilley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

7.  Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin.

Authors:  T Uchida; S Martin; T P Foster; R C Wardley; S Grimm
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

8.  Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres.

Authors:  C O Tacket; R H Reid; E C Boedeker; G Losonsky; J P Nataro; H Bhagat; R Edelman
Journal:  Vaccine       Date:  1994-11       Impact factor: 3.641

9.  Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae.

Authors:  D H Jones; B W McBride; H Jeffery; D T O'Hagan; A Robinson; G H Farrar
Journal:  Vaccine       Date:  1995-05       Impact factor: 3.641

10.  Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.

Authors:  E S Cahill; D T O'Hagan; L Illum; A Barnard; K H Mills; K Redhead
Journal:  Vaccine       Date:  1995-04       Impact factor: 3.641

View more
  12 in total

1.  Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice.

Authors:  T Jung; W Kamm; A Breitenbach; K D Hungerer; E Hundt; T Kissel
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 3.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 4.  The intestinal uptake of particles and the implications for drug and antigen delivery.

Authors:  D T O'Hagan
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

5.  Probiotic Lactobacillus johnsonii BS15 Promotes Growth Performance, Intestinal Immunity, and Gut Microbiota in Piglets.

Authors:  Jinge Xin; Dong Zeng; Hesong Wang; Ning Sun; Ying Zhao; Yan Dan; Kangcheng Pan; Bo Jing; Xueqin Ni
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

6.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

7.  A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor.

Authors:  I Chen; T M Finn; L Yanqing; Q Guoming; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

8.  Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles.

Authors:  S C Chen; D H Jones; E F Fynan; G H Farrar; J C Clegg; H B Greenberg; J E Herrmann
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents.

Authors:  R Audran; Y Men; P Johansen; B Gander; G Corradin
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

10.  Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.

Authors:  E J Ryan; E McNeela; G A Murphy; H Stewart; D O'hagan; M Pizza; R Rappuoli; K H Mills
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.